BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 30061359)

  • 1. Sunitinib Prior to Planned Nephrectomy in Metastatic Renal Cell Carcinoma: Angiogenesis Biomarkers Predict Clinical Outcome in the Prospective Phase II PREINSUT Trial.
    Mauge L; Mejean A; Fournier L; Pereira H; Etienne-Grimaldi MC; Levionnois E; Caty A; Abadie-Lacourtoisie S; Culine S; Le Moulec S; Linassier C; Théodore C; Ravaud A; Albiges L; Grine A; Tartour E; Milano G; Gille AS; Verkarre V; Helley D; Oudard S;
    Clin Cancer Res; 2018 Nov; 24(22):5534-5542. PubMed ID: 30061359
    [No Abstract]   [Full Text] [Related]  

  • 2. Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers.
    Kontovinis LF; Papazisis KT; Touplikioti P; Andreadis C; Mouratidou D; Kortsaris AH
    BMC Cancer; 2009 Mar; 9():82. PubMed ID: 19284623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
    Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
    J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumour cell expression of interleukin 6 receptor α is associated with response rates in patients treated with sunitinib for metastatic clear cell renal cell carcinoma.
    Pilskog M; Bostad L; Edelmann RJ; Akslen LA; Beisland C; Straume O
    J Pathol Clin Res; 2018 Apr; 4(2):114-123. PubMed ID: 29665322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.
    Bex A; Mulders P; Jewett M; Wagstaff J; van Thienen JV; Blank CU; van Velthoven R; Del Pilar Laguna M; Wood L; van Melick HHE; Aarts MJ; Lattouf JB; Powles T; de Jong Md PhD IJ; Rottey S; Tombal B; Marreaud S; Collette S; Collette L; Haanen J
    JAMA Oncol; 2019 Feb; 5(2):164-170. PubMed ID: 30543350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TARIBO trial: targeted therapy with or without nephrectomy in metastatic renal cell carcinoma: liquid biopsy for biomarkers discovery.
    Verzoni E; Ratta R; Grassi P; Salvioni R; Stagni S; Montone R; Fucà G; Cappelletti V; Reduzzi C; De Giorgi U; Procopio G
    Tumori; 2018 Oct; 104(5):401-405. PubMed ID: 29192741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.
    Grivas PD; Daignault S; Tagawa ST; Nanus DM; Stadler WM; Dreicer R; Kohli M; Petrylak DP; Vaughn DJ; Bylow KA; Wong SG; Sottnik JL; Keller ET; Al-Hawary M; Smith DC; Hussain M
    Cancer; 2014 Mar; 120(5):692-701. PubMed ID: 24249435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma.
    Rautiola J; Donskov F; Peltola K; Joensuu H; Bono P
    BJU Int; 2016 Jan; 117(1):110-7. PubMed ID: 25252180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomised Phase II study comparing alternating cycles of sunitinib and everolimus vs standard sequential administration in first-line metastatic renal carcinoma (SUNRISES study).
    Rodriguez-Vida A; Bamias A; Esteban E; Saez MI; Lopez-Brea M; Castellano D; Caballero C; Gonzalez-Larriba JL; Calvo E; Macia S; Ravaud A; Bellmunt J
    BJU Int; 2020 Nov; 126(5):559-567. PubMed ID: 32654362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Angiopoietin-2 and Ki-67 Expression with Vascular Density and Sunitinib Response in Metastatic Renal Cell Carcinoma.
    Rautiola J; Lampinen A; Mirtti T; Ristimäki A; Joensuu H; Bono P; Saharinen P
    PLoS One; 2016; 11(4):e0153745. PubMed ID: 27100185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
    Xie M; He CS; Huang JK; Lin QZ
    Eur J Cancer; 2015 Mar; 51(5):595-603. PubMed ID: 25618828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.
    Powles T; Blank C; Chowdhury S; Horenblas S; Peters J; Shamash J; Sarwar N; Boleti E; Sahdev A; O'Brien T; Berney D; Beltran L; Nathan P; Haanen J; Bex A
    Eur Urol; 2011 Sep; 60(3):448-54. PubMed ID: 21612860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamic biomarker and imaging changes from a phase II study of pre- and post-surgical sunitinib.
    Welsh SJ; Thompson N; Warren A; Priest AN; Barrett T; Ursprung S; Gallagher FA; Zaccagna F; Stewart GD; Fife KM; Matakidou A; Machin AJ; Qian W; Ingleson V; Mullin J; Riddick ACP; Armitage JN; Connolly S; Eisen TGQ
    BJU Int; 2022 Aug; 130(2):244-253. PubMed ID: 34549873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α.
    Tsimafeyeu I; Zart JS; Chung B
    BJU Int; 2013 Jul; 112(1):32-8. PubMed ID: 23746142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression level of vascular endothelial growth factor receptor-2 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with sunitinib.
    Terakawa T; Miyake H; Kusuda Y; Fujisawa M
    Urol Oncol; 2013 May; 31(4):493-8. PubMed ID: 21478036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Negative Effect of Immediate Sunitinib Interruption on Survival in Patients With Metastatic Renal Cell Carcinoma.
    Ishiyama R; Ishihara H; Kondo T; Takagi T; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
    In Vivo; 2019; 33(6):2153-2160. PubMed ID: 31662551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is there a "Trial Effect" on Outcome of Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib?
    Keizman D; Rouvinov K; Sella A; Gottfried M; Maimon N; Kim JJ; Eisenberger MA; Sinibaldi V; Peer A; Carducci MA; Mermershtain W; Leibowitz-Amit R; Weitzen R; Berger R
    Cancer Res Treat; 2016 Jan; 48(1):281-7. PubMed ID: 25761478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pro-angiogenic gene expression is associated with better outcome on sunitinib in metastatic clear-cell renal cell carcinoma.
    Beuselinck B; Verbiest A; Couchy G; Job S; de Reynies A; Meiller C; Albersen M; Verkarre V; Lerut E; Méjean A; Patard JJ; Laguerre B; Rioux-Leclercq N; Schöffski P; Oudard S; Zucman-Rossi J
    Acta Oncol; 2018 Apr; 57(4):498-508. PubMed ID: 29095068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ιmpact of sunitinib-induced hypothyroidism on survival of patients with metastatic renal cancer.
    Vasileiadis T; Chrisofos M; Safioleas M; Kontzoglou K; Papazisis K; Sdrolia A
    BMC Cancer; 2019 Apr; 19(1):407. PubMed ID: 31039771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamic Contrast-Enhanced Computed Tomography-Derived Blood Volume and Blood Flow Correlate With Patient Outcome in Metastatic Renal Cell Carcinoma.
    Mains JR; Donskov F; Pedersen EM; Madsen HH; Rasmussen F
    Invest Radiol; 2017 Feb; 52(2):103-110. PubMed ID: 27513367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.